A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.
Open accessThe DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
BACKGROUND: In two of three phase 3 trials, pirfenidone, an oral antifibrotic therapy, reduced disease progression, as measured by the decline in forced vital capacity (FVC) or vital capacity, in patients with idiopathic pulmonary fibrosis; in the third trial, this end point was not achieved. We sought to confirm the beneficial effect of pirfenidone on disease progression in such patients. METHODS: In this phase 3 study, we randomly assigned 555 patients with idiopathic pulmonary fibrosis to receive either oral pirfenidone (2403 mg per day) or placebo for 52 weeks. The primary end point was the change in FVC or death at week 52. Secondary end points were the 6-minute walk distance, progression-free survival, dyspnea, and death from any cause or from idiopathic pulmonary fibrosis. RESULTS: In the pirfenidone group, as compared with the placebo group, there was a relative reduction of 47.9% in the proportion of patients who had an absolute decline of 10 percentage points or more in the percentage of the predicted FVC or who died; there was also a relative increase of 132.5% in the proportion of patients with no decline in FVC (P<0.001). Pirfenidone reduced the decline in the 6-minute walk distance (P=0.04) and improved progression-free survival (P<0.001). There was no significant between-group difference in dyspnea scores (P=0.16) or in rates of death from any cause (P=0.10) or from idiopathic pulmonary fibrosis (P=0.23). However, in a prespecified pooled analysis incorporating results from two previous phase 3 trials, the between-group difference favoring pirfenidone was significant for death from any cause (P=0.01) and from idiopathic pulmonary fibrosis (P=0.006). Gastrointestinal and skin-related adverse events were more common in the pirfenidone group than in the placebo group but rarely led to treatment discontinuation. CONCLUSIONS: Pirfenidone, as compared with placebo, reduced disease progression, as reflected by lung function, exercise tolerance, and progression-free survival, in patients with idiopathic pulmonary fibrosis. Treatment was associated with an acceptable side-effect profile and fewer deaths. (Funded by InterMune; ASCEND ClinicalTrials.gov number, NCT01366209.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Idiopathic pulmonary fibrosis (IPF), the prototype of fibrotic ILDs, carries a prognosis of 3–5 years survival after diagnosis when untreated. Two anti-fibrotic medications (nintedanib and pirfenidone) have been shown to reduce the rate of forced vital capacity (FVC) decline and slow disease progression in patients with a definite usual interstitial pneumonia (UIP) pattern and with a probable UIP pattern on high resolution CT (HRCT).(191–193)”
From Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation. (2021) · cites this paper as [191]
In the citing paper
“However, both have significant adverse effects and neither completely arrest the decline in lung function.”
From Emerging pharmacological options in the treatment of idiopathic pulmonary fibrosis (IPF) (2024) · cites this paper as [13]
In the citing paper
“In three trials with doses that reached 2403 mg/day, pirfenidone effectively reduced FVC decline although had variable reductions in overall mortality and IPF-related mortality [12,13].”
From Emerging pharmacological options in the treatment of idiopathic pulmonary fibrosis (IPF) (2024) · cites this paper as [13]
In the citing paper
“Reported adverse events in the present trial were generally acceptable and largely consistent with events previously reported by participants in the placebo arms of randomized controlled trials in IPF [45,46].”
From Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study (2019) · cites this paper as [45]
In the citing paper
“FVC is the gold-standard metric for assessing the lung function of patients with IPF and response to therapeutic intervention33–35.”
From A generative AI-discovered TNIK inhibitor for idiopathic pulmonary fibrosis: a randomized phase 2a trial (2025) · cites this paper as [35]
9 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Miller, M. R., Hankinson, J., Brusasco, V., Burgos, F., Casaburi, R., Coates, A., Crapo, R., Enright, P., van der Grinten, C. P. M., Gustafsson, P., et al. (2005) · European Respiratory Journal · doi:10.1183/09031936.05.00034805 · Cited by 15,627
Raghu, G., Collard, H. R., Egan, J. J., Martinez, F. J., Behr, J., Brown, K. K., Colby, T. V., Cordier, J.-F., Flaherty, K. R., Lasky, J. A., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.2009-040gl · Cited by 7,186
Self-citationA sharper Bonferroni procedure for multiple tests of significance
HOCHBERG, Y. (1988) · Biometrika · doi:10.1093/biomet/75.4.800 · Cited by 4,829
Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials
Noble, P. W., Albera, C., Bradford, W. Z., Costabel, U., Glassberg, M. K., Kardatzke, D., King, T. E., Lancaster, L., Sahn, S. A., Szwarcberg, J., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60405-4 · Cited by 2,154
Self-citationDouble-blind, Placebo-controlled Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis
Azuma, A., Nukiwa, T., Tsuboi, E., Suga, M., Abe, S., Nakata, K., Taguchi, Y., Nagai, S., Itoh, H., Ohi, M., et al. (2005) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200404-571oc · Cited by 954
Pirfenidone in idiopathic pulmonary fibrosis
Taniguchi, H., Ebina, M., Kondoh, Y., Ogura, T., Azuma, A., Suga, M., Taguchi, Y., Takahashi, H., Nakata, K., Sato, A., et al. (2010) · European Respiratory Journal · doi:10.1183/09031936.00005209 · Cited by 946
Pirfenidone in idiopathic pulmonary fibrosis: Figure 1–
Swigris, J., & Fairclough, D. (2010) · European Respiratory Journal · doi:10.1183/09031936.00071710 · Cited by 799
Self-citationChanges in Clinical and Physiologic Variables Predict Survival in Idiopathic Pulmonary Fibrosis
Collard, H. R., King, T. E., Bartelson, B. B., Vourlekis, J. S., Schwarz, M. I., & Brown, K. K. (2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200211-1311oc · Cited by 764
Self-citationThe Clinical Course of Patients with Idiopathic Pulmonary Fibrosis
Martinez, F. J., Safrin, S., Weycker, D., Starko, K. M., Bradford, W. Z., King, T. E., Flaherty, K. R., Schwartz, D. A., Noble, P. W., Raghu, G., et al. (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-142-12_part_1-200506210-00005 · Cited by 622
Self-citationKing, T. E., Albera, C., Bradford, W. Z., Costabel, U., Hormel, P., Lancaster, L., Noble, P. W., Sahn, S. A., Szwarcberg, J., Thomeer, M., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60551-1 · Cited by 531
Self-citation
Cited by
Items 401–500 of 3,965
mTOR Overactivation and Compromised Autophagy in the Pathogenesis of Pulmonary Fibrosis
Gui, Y.-S., Wang, L., Tian, X., Li, X., Ma, A., Zhou, W., Zeng, N., Zhang, J., Cai, B., Zhang, H., et al. (2015) · PLOS ONE · doi:10.1371/journal.pone.0138625 · Cited by 94
Iwata, T., Yoshida, S., Fujiwara, T., Wada, H., Nakajima, T., Suzuki, H., & Yoshino, I. (2016) · The Annals of Thoracic Surgery · doi:10.1016/j.athoracsur.2016.05.094 · Cited by 105
Evaluating disease severity in idiopathic pulmonary fibrosis
Robbie, H., Daccord, C., Chua, F., & Devaraj, A. (2017) · European Respiratory Review · doi:10.1183/16000617.0051-2017 · Cited by 93
Idiopathic pulmonary fibrosis and cancer: do they really look similar?
Vancheri, C. (2015) · BMC Medicine · doi:10.1186/s12916-015-0478-1 · Cited by 94
Antacid therapy in idiopathic pulmonary fibrosis: more questions than answers?
Johannson, K. A., Strambu, I. R., Ravaglia, C., Grutters, J. C., Valenzuela, C., Moğulkoç, N., Luppi, F., Richeldi, L., Wells, A. U., Vancheri, C., et al. (2017) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(17)30219-9 · Cited by 101
Marshall, D. C., Salciccioli, J. D., Shea, B. S., & Akuthota, P. (2018) · European Respiratory Journal · doi:10.1183/13993003.01603-2017 · Cited by 101
LOX/LOXL in pulmonary fibrosis: potential therapeutic targets
Chen, L., Li, S., & Li, W. (2018) · Journal of drug targeting · doi:10.1080/1061186x.2018.1550649 · Cited by 96
on behalf of the IPF-PRO Registry investigators, Todd, J. L., Neely, M. L., Overton, R., Durham, K., Gulati, M., Huang, H., Roman, J., Newby, L. K., Flaherty, K. R., et al. (2019) · Respiratory Research · doi:10.1186/s12931-019-1190-z · Cited by 93
Tzilas, V., Bouros, E., Barbayianni, I., Karampitsakos, T., Kourtidou, S., Ntassiou, M., Ninou, I., Aidinis, V., Bouros, D. E., & Τzouvelekis, Α. (2019) · Pulmonary Pharmacology & Therapeutics · doi:10.1016/j.pupt.2019.01.003 · Cited by 104
Shao, D., Liu, X., Wu, J., Zhang, A., Bai, Y., Zhao, P., & Li, J. (2022) · Phytomedicine · doi:10.1016/j.phymed.2022.154177 · Cited by 97
Acute exacerbation of idiopathic pulmonary fibrosis-a review of current and novel pharmacotherapies.
Juarez, M. M., Chan, A. L., Norris, A., Morrissey, B. M., & Albertson, T. E. (2015) · PubMed Central · doi:10.3978/j.issn.2072-1439.2015.01.17 · Cited by 114
Raghu, G., Ghazipura, M., Fleming, T. R., Aronson, K. I., Behr, J., Brown, K. K., Flaherty, K. R., Kazerooni, E. A., Maher, T. M., Richeldi, L., et al. (2024) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202312-2213so · Cited by 92
Self-citationCurrent approaches to the management of idiopathic pulmonary fibrosis
Raghu, G., & Richeldi, L. (2017) · Respiratory Medicine · doi:10.1016/j.rmed.2017.05.017 · Cited by 90
The Role of TGF-β Signaling in Lung Cancer Associated with Idiopathic Pulmonary Fibrosis
Saito, A., Horie, M., Micke, P., & Nagase, T. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19113611 · Cited by 90
“These agents slow disease progression [98,99], and recent meta-analyses have demonstrated that these agents have a beneficial impact on survival [100,101].”
BackgroundIdiopathic Pulmonary Fibrosis: Epidemiology, Diagnosis andOutcomes
Wakwaya, Y. T., & Brown, K. M. (2019) · The American Journal of the Medical Sciences · doi:10.1016/j.amjms.2019.02.013 · Cited by 97
TAZ is required for lung alveolar epithelial cell differentiation after injury
Sun, T., Huang, Z., Zhang, H., Posner, C., Jia, G., Ramalingam, T. R., Xu, M., Brightbill, H., Egen, J. G., Dey, A., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.128674 · Cited by 90
“For human plasma samples, IPF patients described in this study are a subset of the ASCEND study and are reported in detail previously (53).”
MethodLung transplantation for interstitial lung disease
Kapnadak, S. G., & Raghu, G. (2021) · European Respiratory Review · doi:10.1183/16000617.0017-2021 · Cited by 91
Handa, T., Tanizawa, K., Oguma, T., Uozumi, R., Watanabe, K., Tanabe, N., Niwamoto, T., Shima, H., Mori, R., Nobashi, T. W., et al. (2022) · Annals of the American Thoracic Society · doi:10.1513/annalsats.202101-044oc · Cited by 104
The cytokines of pulmonary fibrosis: Much learned, much more to learn
Luzina, I. G., Todd, N. W., Sundararajan, S., & Atamas, S. P. (2014) · Cytokine · doi:10.1016/j.cyto.2014.11.008 · Cited by 100
Lung cancer in idiopathic pulmonary fibrosis: A systematic review and meta-analysis
Jafarinezhad, A., & YektaKooshali, M. H. (2018) · PLoS ONE · doi:10.1371/journal.pone.0202360 · Cited by 98
Cameli, P., Refini, R. M., Bergantini, L., d’Alessandro, M., Alonzi, V., Magnoni, C., Rottoli, P., Sestini, P., & Bargagli, E. (2020) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2020.581828 · Cited by 89
Genetic Evaluation and Testing of Patients and Families with Idiopathic Pulmonary Fibrosis
Kropski, J. A., Young, L. R., Cogan, J. D., Mitchell, D. B., LANCASTER, L. H., Worrell, J. A., Markin, C. R., Liu, N., Mason, W. R., Fingerlin, T. E., et al. (2017) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201609-1820pp · Cited by 104
Self-citationNintedanib for the treatment of idiopathic pulmonary fibrosis
Varone, F., Sgalla, G., Iovene, B., Bruni, T., & Richeldi, L. (2018) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1425681 · Cited by 98
Pirfenidone for idiopathic pulmonary fibrosis and beyond
Aimo, A., Spitaleri, G., Nieri, D., Tavanti, L. M., Meschi, C., Panichella, G., Lupón, J., Pistelli, F., Carrozzi, L., Bayes-Genis, A., et al. (2022) · Cardiac Failure Review · doi:10.15420/cfr.2021.30 · Cited by 88
Kreuter, M., Bonella, F., Wijsenbeek, M., Maher, T. M., & Spagnolo, P. (2015) · BioMed Research International · doi:10.1155/2015/329481 · Cited by 87
Çınar, R., Gochuico, B. R., Iyer, M. R., Jourdan, T., Yokoyama, T., Park, J. K., Coffey, N. J., Pri‐Chen, H., Szanda, G., Liu, Z., et al. (2017) · JCI Insight · doi:10.1172/jci.insight.92281 · Cited by 97
Moor, C. C., Oppenheimer, J. C., Nakshbandi, G., Aerts, J. G. J. V., Brinkman, P., der Zee, A. H. M., & Wijsenbeek, M. S. (2020) · European Respiratory Journal · doi:10.1183/13993003.02042-2020 · Cited by 93
Doubková, M., Švancara, J., Svoboda, M., Šterclová, M., Bartoš, V., Plačková, M., Lacina, L., Žurková, M., Binková, I., Bittenglová, R., et al. (2018) · The Clinical Respiratory Journal · doi:10.1111/crj.12700 · Cited by 87
Kim, J.-H., An, G. H., Kim, J.-Y., Rasaei, R., Kim, W. J., Jin, X., Woo, D.-H., Han, C., Yang, S.-R., Kim, J.-H., et al. (2021) · Cell Death Discovery · doi:10.1038/s41420-021-00439-7 · Cited by 87
Recent advances in understanding idiopathic pulmonary fibrosis
Daccord, C., & Maher, T. M. (2016) · F1000Research · doi:10.12688/f1000research.8209.1 · Cited by 87
Comorbid Conditions in Idiopathic Pulmonary Fibrosis: Recognition and Management
Oldham, J. M., & Collard, H. R. (2017) · Frontiers in Medicine · doi:10.3389/fmed.2017.00123 · Cited by 98
Dhooria, S., Agarwal, R., Sehgal, I. S., Prasad, K. T., Garg, M. K., Bal, A., Aggarwal, A. N., & Behera, D. (2018) · PLoS ONE · doi:10.1371/journal.pone.0191938 · Cited by 95
Pirfenidone improves survival in IPF: results from a real-life study
Margaritopoulos, G. A., Trachalaki, A., Wells, A. U., Vasarmidi, E., Bibaki, E., Papastratigakis, G., Detorakis, S., Tzanakis, N., & Antoniou, K. M. (2018) · BMC Pulmonary Medicine · doi:10.1186/s12890-018-0736-z · Cited by 87
Gas6/TAM System: A Key Modulator of the Interplay between Inflammation and Fibrosis
Bellan, M., Cittone, M. G., Tonello, S., Rigamonti, C., Castello, L. M., Gavelli, F., Pirisi, M., & Sainaghi, P. P. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20205070 · Cited by 85
Recovering from a pandemic: pulmonary fibrosis after SARS-CoV-2 infection
Mylvaganam, R. J., Bailey, J. I., Sznajder, J. I., & Sala, M. A. (2021) · European Respiratory Review · doi:10.1183/16000617.0194-2021 · Cited by 105
Multiscale drug screening for cardiac fibrosis identifies MD2 as a therapeutic target
Zhang, H., Thai, P. N., Shivnaraine, R. V., Ren, L., Wu, X., Siepe, D. H., Liu, Y., Tu, C., Shin, H. S., Caudal, A., et al. (2024) · Cell · doi:10.1016/j.cell.2024.09.034 · Cited by 102
Dong, S.-H., Liu, Y., Wei, F., Tan, H., & Han, Z.-D. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.03.005 · Cited by 89
Home monitoring improves endpoint efficiency in idiopathic pulmonary fibrosis
Johannson, K. A., Vittinghoff, E., Morisset, J., Lee, J. S., Balmes, J. R., & Collard, H. R. (2017) · European Respiratory Journal · doi:10.1183/13993003.02406-2016 · Cited by 101
Pirfenidone plus inhaled N-acetylcysteine for idiopathic pulmonary fibrosis: a randomised trial
Sakamoto, S., Kataoka, K., Kondoh, Y., Kato, M., Okamoto, M., Mukae, H., Bando, M., Suda, T., Yatera, K., Tanino, Y., et al. (2021) · European Respiratory Journal · doi:10.1183/13993003.00348-2020 · Cited by 67
Tian, S., Yang, Y., Liu, X., & Xu, Q. (2018) · Medical Science Monitor · doi:10.12659/msm.905496 · Cited by 86
Durheim, M. T., Collard, H. R., Roberts, R. S., Brown, K. K., Flaherty, K. R., King, T. E., Palmer, S. M., Raghu, G., Snyder, L. D., Anstrom, K. J., et al. (2015) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(15)00093-4 · Cited by 87
Self-citationGilhodes, J.-C., Julé, Y., Kreuz, S., Stierstorfer, B., Stiller, D., & Wollin, L. (2017) · PLoS ONE · doi:10.1371/journal.pone.0170561 · Cited by 98
Lung complications of Sjogren syndrome
Luppi, F., Sebastiani, M., Sverzellati, N., Cavazza, A., Salvarani, C., & Manfredi, A. (2020) · European Respiratory Review · doi:10.1183/16000617.0021-2020 · Cited by 99
Pulmonary fibrosis: from mechanisms to therapies
Jiang, M., Bu, W., Wang, X., Ruan, J., Shi, W., Yu, S., Huang, L., Xue, P., Tang, J., Zhao, X., et al. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-06514-2 · Cited by 120
Effect of statins on disease-related outcomes in patients with idiopathic pulmonary fibrosis
Kreuter, M., Bonella, F., Maher, T. M., Costabel, U., Spagnolo, P., Weycker, D., Kirchgaessler, K.-U., & Kolb, M. (2017) · Thorax · doi:10.1136/thoraxjnl-2016-208819 · Cited by 85
Uncoupling of the profibrotic and hemostatic effects of thrombin in lung fibrosis
Shea, B. S., Probst, C. K., Brazee, P. L., Rotile, N. J., Blasi, F., Weinreb, P. H., Black, K. E., Sosnovik, D. E., Cott, E. M. V., Violette, S. M., et al. (2017) · JCI Insight · doi:10.1172/jci.insight.86608 · Cited by 88
Idiopathic pulmonary fibrosis: Recent advances on pharmacological therapy
Spagnolo, P., Maher, T. M., & Richeldi, L. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2015.04.005 · Cited by 94
Sohal, S. S., Mahmood, M. Q., & Walters, E. H. (2014) · Clinical and Translational Medicine · doi:10.1186/s40169-014-0033-2 · Cited by 86
Telomeres in Interstitial Lung Disease: The Short and the Long of It
Courtwright, A., & El‐Chemaly, S. (2018) · Annals of the American Thoracic Society · doi:10.1513/annalsats.201808-508cme · Cited by 88
Restrictive chronic lung allograft dysfunction: Where are we now?
Verleden, S. E., Ruttens, D., Vandermeulen, E., Bellon, H., Raemdonck, D. E. V., Dupont, L., Vanaudenaerde, B. M., Verleden, G. M., & Vos, R. (2014) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2014.11.007 · Cited by 83
Pharmacologic inhibition of lactate production prevents myofibroblast differentiation
Kottmann, R. M., Trawick, E. C., Judge, J., Wahl, L. A., Epa, A. P., Owens, K. M., Thatcher, T. H., Phipps, R. P., & Sime, P. J. (2015) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00058.2015 · Cited by 91
Risk Factors for the Development of Idiopathic Pulmonary Fibrosis: a Review
Zaman, T., & Lee, J. S. (2018) · Current Pulmonology Reports · doi:10.1007/s13665-018-0210-7 · Cited by 97
Long‐term outcomes in chronic hypersensitivity pneumonitis
Ojanguren, Í., Morell, F., Ramón, M. A., Villar, A., Mesones, C. E. R., Cruz, M. J., & Muñoz, X. (2019) · Allergy · doi:10.1111/all.13692 · Cited by 91
“Indeed, in similar processes such as IPF or connective tissue disease‐associated ILD, which show a reduction in these parameters as occurs in CHP,(31,32) there is increasing consensus to adding DLCO values not only for the diagnosis and management,(33) but also for evaluating response to new drugs in clinical trials.(…”
Backgroundp38γ MAPK Is Essential for Aerobic Glycolysis and Pancreatic Tumorigenesis
Wang, F., Qi, X.-M., Wertz, R., Mortensen, M., Hagen, C. E., Evans, J., Sheinin, Y. M., James, M. A., Liu, P., Tsai, S., et al. (2020) · Cancer Research · doi:10.1158/0008-5472.can-19-3281 · Cited by 91
Margaritopoulos, G., Vasarmidi, E., & Antoniou, K. (2016) · Core Evidence · doi:10.2147/ce.s76549 · Cited by 81
Rubio, K., Singh, I., Dobersch, S., Sarvari, P., Günther, S., Cordero, J., Mehta, A., Wujak, L. A., Cabrera-Fuentes, H. A., Chao, C., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-10066-7 · Cited by 88
Adegunsoye, A., Alqalyoobi, S., Linderholm, A., Bowman, W. S., Lee, C. T., Pugashetti, J. V., Sarma, N., Ma, S.-F., Haczku, A., Sperling, A., et al. (2020) · Chest · doi:10.1016/j.chest.2020.04.066 · Cited by 82
Lung Fibrosis and Fibrosis in the Lungs: Is It All about Myofibroblasts?
Zapater, E. O., Signes‐Costa, J., Montero, P., & Roger, I. (2022) · Biomedicines · doi:10.3390/biomedicines10061423 · Cited by 94
Pulmonary inflammation and fibroblast immunoregulation: from bench to bedside
Ghonim, M. A., Boyd, D. F., Flerlage, T., & Thomas, P. G. (2023) · Journal of Clinical Investigation · doi:10.1172/jci170499 · Cited by 95
Ahamed, J., & Laurence, J. C. (2017) · Antioxidants and Redox Signaling · doi:10.1089/ars.2017.7064 · Cited by 88
Pirfenidone exerts antifibrotic effects through inhibition of GLI transcription factors
Didiášová, M., Singh, R. K., Wilhelm, J., Kwapiszewska, G., Wujak, L. A., Zakrzewicz, D., Schaefer, L., Markart, P., Seeger, W., Lauth, M., et al. (2017) · The FASEB Journal · doi:10.1096/fj.201600892rr · Cited by 86
Treatment of Interstitial Lung Disease Associated Cough
Birring, S. S., Kavanagh, J. E., Irwin, R. S., Keogh, K. A., Lim, K. G., Ryu, J. H., Adams, T. M., Altman, K. W., Azoulay, É., Barker, A. F., et al. (2018) · CHEST Journal · doi:10.1016/j.chest.2018.06.038 · Cited by 87
Abramson, M. J., Murambadoro, T., Alif, S. M., Benke, G. P., Dharmage, S. C., Glaspole, I., Hopkins, P., Hoy, R. F., Klebe, S., Moodley, Y., et al. (2020) · Thorax · doi:10.1136/thoraxjnl-2019-214478 · Cited by 80
Self-citationThe Pulmonary Fibrosis Foundation Patient Registry. Rationale, Design, and Methods
Wang, B. R., Edwards, R., Freiheit, E., Ma, Y., Burg, C., de Andrade, J. A., LANCASTER, L. H., Lindell, K. O., Nathan, S. D., Raghu, G., et al. (2020) · Annals of the American Thoracic Society · doi:10.1513/annalsats.202001-035sd · Cited by 84
Self-citationRegulatory Immune Cells in Idiopathic Pulmonary Fibrosis: Friends or Foes?
van Geffen, C., Deißler, A., Quante, M., Renz, H. E., Hartl, D., & Kolahian, S. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.663203 · Cited by 88
Small Airway Reduction and Fibrosis Is an Early Pathologic Feature of Idiopathic Pulmonary Fibrosis
Ikezoe, K., Hackett, T., Peterson, S., Prins, D., Hague, C. J., Murphy, D. T., Ledoux, S., Chu, F. S. F., Xu, F., Cooper, J. D., et al. (2021) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202103-0585oc · Cited by 90
Telomere length and immunosuppression in non-idiopathic pulmonary fibrosis interstitial lung disease
Zhang, D., Adegunsoye, A., Oldham, J. M., Kozlitina, J., Garcia, N. M., Poonawalla, M., Strykowski, R. K., Linderholm, A., Ley, B., Ma, S., et al. (2023) · European Respiratory Journal · doi:10.1183/13993003.00441-2023 · Cited by 95
Park, H. J., Lee, S. M., Song, J. W., Lee, S. M., Oh, S. Y., Kim, N., & Seo, J. B. (2016) · American Journal of Roentgenology · doi:10.2214/ajr.16.16054 · Cited by 88
Bexotegrast in Patients with Idiopathic Pulmonary Fibrosis: The INTEGRIS-IPF Clinical Trial
Lancaster, L., Cottin, V., Ramaswamy, M., Wuyts, W. A., Jenkins, R. G., Scholand, M. B., Kreuter, M., Valenzuela, C., Ryerson, C. J., Goldin, J., et al. (2024) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202403-0636oc · Cited by 80
Self-citationJee, A. S., Adelstein, S., Bleasel, J. F., Keir, G. J., Nguyen, M., Sahhar, J., Youssef, P. P., & Corte, T. J. (2017) · Journal of Clinical Medicine · doi:10.3390/jcm6050051 · Cited by 88
Wong, A. W., Fidler, L. M., Marcoux, V. S., Johannson, K. A., Assayag, D., Fisher, J. H., Hambly, N., Kolb, M. R. J., Morisset, J., Shapera, S., et al. (2020) · CHEST Journal · doi:10.1016/j.chest.2020.04.019 · Cited by 94
“[24] [25] [26] The current difficulty in obtaining PFTs and conducting MDDs in places with a high burden of COVID-19 will limit fulfillment of these criteria.”
Phase 2 trial to assess lebrikizumab in patients with idiopathic pulmonary fibrosis
Maher, T. M., Costabel, U., Glassberg, M. K., Kondoh, Y., Ogura, T., Scholand, M. B., Kardatzke, D., Howard, M., Olsson, J., Neighbors, M., et al. (2021) · European Respiratory Journal · doi:10.1183/13993003.02442-2019 · Cited by 79
Self-citationLin, S., Mao, R., Qian, C., Bettenworth, D., Wang, J., Li, J., Bruining, D. H., Jairath, V., Feagan, B. G., Chen, M., et al. (2021) · Physiological Reviews · doi:10.1152/physrev.00005.2021 · Cited by 91
Pamrevlumab for Idiopathic Pulmonary Fibrosis: The ZEPHYRUS-1 Randomized Clinical Trial
Raghu, G., Richeldi, L., Pérez, E. R. F., Salvo, M. C. D., Silva, R. S., Song, J. W., Ogura, T., Xu, Z., Belloli, E. A., Zhang, X., et al. (2024) · JAMA · doi:10.1001/jama.2024.8693 · Cited by 104
Self-citationMiura, Y., Saito, T., Tanaka, T., Takoi, H., Yatagai, Y., Inomata, M., Nei, T., Saito, Y., Gemma, A., & Azuma, A. (2017) · Respiratory Investigation · doi:10.1016/j.resinv.2017.09.007 · Cited by 94
Kwapiszewska, G., Gungl, A., Wilhelm, J., Marsh, L. M., Thekkekara Puthenparampil, H., Sinn, K., Didiasova, M., Klepetko, W., Kosanovic, D., Schermuly, R. T., et al. (2018) · European Respiratory Journal · doi:10.1183/13993003.00564-2018 · Cited by 80
Transbronchial cryobiopsy in interstitial lung disease: experience in 106 cases – how to do it
Bango, A., Ariza‐Prota, M., Rivas, H. E. T., Fernández, L., Prieto, A., Sánchez, I., Gil, M., & Pando‐Sandoval, A. (2017) · ERJ Open Research · doi:10.1183/23120541.00148-2016 · Cited by 82
Schwarzkopf, L., Witt, S., Waelscher, J., Polke, M., & Kreuter, M. (2018) · Respiratory Research · doi:10.1186/s12931-018-0769-0 · Cited by 83
Nathan, S. D., Costabel, U., Albera, C., Behr, J., Wuyts, W. A., Kirchgaessler, K.-U., Stauffer, J. L., Morgenthien, E., Chou, W., Limb, S. L., et al. (2019) · Respiratory Medicine · doi:10.1016/j.rmed.2019.04.016 · Cited by 79
Self-citationImaging research in fibrotic lung disease; applying deep learning to unsolved problems
Walsh, S. L. F., Humphries, S. M., Wells, A. U., & Brown, K. K. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(20)30003-5 · Cited by 94
Pulmonary Resection for Lung Cancer in Patients With Idiopathic Interstitial Pneumonia
Omori, T., Tajiri, M., Baba, T., Ogura, T., Iwasawa, T., Okudela, K., Takemura, T., Oba, M. S., Maehara, T., Nakayama, H., et al. (2015) · The Annals of Thoracic Surgery · doi:10.1016/j.athoracsur.2015.03.094 · Cited by 85
Flores-Contreras, L., Sandoval-Rodríguez, A. S., Mena-Enriquez, M. G., Lucano-Landeros, S., Arellano-Olivera, I., Álvarez-Álvarez, A., Sanchez-Parada, M. G., & Armendáriz-Borunda, J. (2014) · BMC Gastroenterology · doi:10.1186/1471-230x-14-131 · Cited by 79
“PFD in the clinical scenario when it comes to treat patients with these fibrotic illnesses [22,23].”
BackgroundEnomoto, N., Mikamo, M., Oyama, Y., Kono, M., Hashimoto, D., Fujisawa, T., Inui, N., Nakamura, Y., Yasuda, H., Kato, A., et al. (2015) · BMC Pulmonary Medicine · doi:10.1186/s12890-015-0004-4 · Cited by 82
The diagnosis and management of interstitial lung diseases
Wallis, A., & Spinks, K. (2015) · BMJ · doi:10.1136/bmj.h2072 · Cited by 90
Mesenchymal Stem Cells for the Treatment of Idiopathic Pulmonary Fibrosis
Tzouvelekis, A., Toonkel, R. L., Karampitsakos, Τ., Medapalli, K., Ninou, I., Aidinis, V., Bouros, D. E., & Glassberg, M. K. (2018) · Frontiers in Medicine · doi:10.3389/fmed.2018.00142 · Cited by 82
Self-citationEfficacy of pirfenidone for idiopathic pulmonary fibrosis: An Italian real life study
Harari, S., Caminati, A., Albera, C., Vancheri, C., Poletti, V., Pesci, A., Luppi, F., Saltini, C., Agostini, C., Bargagli, E., et al. (2015) · Respiratory Medicine · doi:10.1016/j.rmed.2015.04.010 · Cited by 78
Ogura, T., Azuma, A., Inoue, Y., Taniguchi, H., Chida, K., Bando, M., Niimi, Y., Kakutani, S., Suga, M., Sugiyama, Y., et al. (2015) · Respiratory Investigation · doi:10.1016/j.resinv.2015.06.001 · Cited by 84
“In addition, the ASCEND trial demonstrated that pirfenidone therapy significantly retarded disease progression [8].”
BackgroundIwata, T., Yoshida, S., Nagato, K., Nakajima, T., Suzuki, H., Tagawa, T., Mizobuchi, T., Ota, S., Nakatani, Y., & Yoshino, I. (2014) · Surgery Today · doi:10.1007/s00595-014-1071-5 · Cited by 81
“Interestingly, pooled data from the ASCEND and CAPACITY [32] trials showed that death related to IPF was significantly reduced among the patients receiving pirfenidone therapy [6].”
BackgroundBurden of Idiopathic Pulmonary Fibrosis Progression: A 5-Year Longitudinal Follow-Up Study
Cottin, V., Schmidt, A., Laura, C., Fanny, P., Céline, F.-M., Lay, K. L., & Bénard, S. (2017) · PLoS ONE · doi:10.1371/journal.pone.0166462 · Cited by 81
Gupta, S., Fink, M. K., Ghosh, A., Tripathi, R., Sinha, P. R., Sharma, A., Hesemann, N. P., Chaurasia, S. S., Giuliano, E. A., & Mohan, R. R. (2018) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.17-23308 · Cited by 83
Yoon, J. H., Nouraie, M. S., Chen, X., Zou, R. H., Sellarés, J., Veraldi, K. L., Chiarchiaro, J., Lindell, K. O., Wilson, D. O., Kaminski, N., et al. (2018) · Respiratory Research · doi:10.1186/s12931-018-0899-4 · Cited by 84
Faverio, P., Giacomi, F. D., Sardella, L., Fiorentino, G., Carone, M., Salerno, F. G., Ora, J., Rogliani, P., Pellegrino, G. M., Papa, G. F. S., et al. (2018) · BMC Pulmonary Medicine · doi:10.1186/s12890-018-0643-3 · Cited by 90
Jo, H. E., Glaspole, I., Moodley, Y., Chapman, S., Ellis, S., Goh, N., Hopkins, P., Keir, G., Mahar, A., Cooper, W., et al. (2018) · BMC Pulmonary Medicine · doi:10.1186/s12890-018-0575-y · Cited by 77
Self-citationPulmonary fibrosis in the era of stratified medicine
Mathai, S. K., Newton, C. A., Schwartz, D. A., & Garcia, C. K. (2016) · Thorax · doi:10.1136/thoraxjnl-2016-209172 · Cited by 77
Idiopathic Pulmonary Fibrosis: Treatment and Prognosis
Fujimoto, H., Kobayashi, T., & Azuma, A. (2015) · Clinical Medicine Insights Circulatory Respiratory and Pulmonary Medicine · doi:10.4137/ccrpm.s23321 · Cited by 89
Kotani, T., Masutani, R., Suzuka, T., Oda, K., Makino, S., & Ii, M. (2017) · Scientific Reports · doi:10.1038/s41598-017-15022-3 · Cited by 81
Justet, A., Klay, D., Porcher, R., Cottin, V., Ahmad, K., Molina‐Molina, M., Nunès, H., Reynaud‐Gaubert, M., Naccache, J. M., Manali, E. D., et al. (2020) · European Respiratory Journal · doi:10.1183/13993003.03198-2020 · Cited by 87
Combined Pulmonary Fibrosis and Emphysema (CPFE) Clinical Features and Management
Hage, R., Gautschi, F., Steinack, C., & Schuurmans, M. M. (2021) · International Journal of COPD · doi:10.2147/copd.s286360 · Cited by 79
Bowman, W. S., Echt, G. A., & Oldham, J. M. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.680997 · Cited by 77
The Role of Nrf2 in Pulmonary Fibrosis: Molecular Mechanisms and Treatment Approaches
Wang, Y., Wei, J., Deng, H., Zheng, L., Yang, H. Y., & Lv, X. (2022) · Antioxidants · doi:10.3390/antiox11091685 · Cited by 95
Metadata
- Authors
- King, T. E., Bradford, W. Z., Castro-Bernardini, S., Fagan, E. A., Glaspole, I., Glassberg, M. K., Gorina, E., Hopkins, P. M., Kardatzke, D., Lancaster, L., Lederer, D. J., Nathan, S. D., Pereira, C. A., Sahn, S. A., Sussman, R., Swigris, J. J., & Noble, P. W.
- Affiliations
- Cedars-Sinai Medical Center (US)
- The Alfred Hospital (AU)
- University of Miami (US)
- Prince Charles Hospital (AU)
- Vanderbilt University Medical Center (US)
- Columbia University Irving Medical Center (US)
- Inova Fairfax Hospital (US)
- Universidade Federal de São Paulo (BR)
- Medical University of South Carolina (US)
- Overlook Medical Center (US)
- National Jewish Health (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-05-29
- Volume
- 370
- Issue
- 22
- Pages
- 2083-2092
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2168666423
- Cited by
- 3,975
- References
- 27
- Citations by year
- 2026: 272 · 2025: 303 · 2024: 371 · 2023: 315 · 2022: 339 · 2021: 412 · 2020: 343 · 2019: 310 · 2018: 335 · 2017: 319 · 2016: 288 · 2015: 279 · 2014: 76
- FWCI
- 256.80
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- UNIFESP Institutional Repository (Universidade Federal de São Paulo) (submittedVersion)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
- Keywords
- pirfenidone, idiopathic pulmonary fibrosis, antifibrotic therapy, forced vital capacity decline, disease progression, mortality, progression-free survival, 6-minute walk distance, dyspnea, gastrointestinal adverse effects, cutaneous adverse events, exercise tolerance, lung function decline, safety and tolerability
- MeSH terms
- Administration, Oral, Adult, Aged, Aged, 80 and over, Antifibrinolytic Agents, Double-Blind Method, Enzyme Inhibitors, Female, Humans, Male, Middle Aged, Pyridones, Vital Capacity, Treatment Outcome, Disease Progression, Idiopathic Pulmonary Fibrosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.